arrow
J

Jesper Eugen-Olsen

herlev and gentofte
H指数:60
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study” [Diabetes Res. Clin. Pract. 222 (2025) 112071]

对“白细胞介素-6、suPAR和hsCRP与1型糖尿病亚临床左心室功能不全的相关性:千与千寻研究”[Diabetes Res. Clin. Pract. 222 (2025) 112071]的勘误

2026-07-010
OAAI
BLOOD BIOMARKER AND RAMAN ANALYSIS OF LEUKOCYTES IN THE MULTICENTER INTELLIGENCE TRIALS: AT THE INTENSIVE CARE UNIT (INTELLIGENCE-1) AND THE EMERGENCY DEPARTMENT (INTELLIGENCE-2)

血液生物标志物和多中心智能试验中白细胞拉曼分析:在重症监护病房(INTELLIGENCE-1)和急诊科(INTELLIGENCE-2)

Shock
IF2.9
2026-01-010
PRE
Soluble urokinase plasminogen activator receptor and interleukin-6 improves prediction of all-cause mortality and major adverse cardiovascular events in Type 1 diabetes

可溶性尿激酶型纤溶酶原激活剂受体和白介素-6可改善对1型糖尿病患者全因死亡和主要不良心血管事件的预测

2025-07-070
OAAI
The Predictive Role of C-Reactive Protein, Leukocyte Cell Count, and Soluble Urokinase Plasminogen Activator Receptor for Pulmonary Sequelae in Hospitalized COVID-19 Survivors: A Prospective Single-Center Cohort Study
2025-03-010
OAAI
Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study
2024-04-183
OA
Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study
2024-02-232
PRE
qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial
2024-02-067
OAAI
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19
2024-01-184
OAAI
suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury
2023-04-1017
OA
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis

可溶性尿激酶纤溶酶原激活物水平增加调节单核细胞功能以促进动脉粥样硬化

2022-12-1530
OAAI